Osteoporosis
Conference Coverage
Gap in osteoporosis diagnosis and treatment stirs concern
A decline in the diagnosis and treatment of osteoporosis has experts worried about a new epidemic of fractures. Fracture liaison services and...
Conference Coverage
Biologic may bring relief for children and adults with XLH syndrome
DENVER – Studies in adults and children with X-Linked hypophosphatemia show benefit with a monoclonal antibody that boosts serum levels of...
Conference Coverage
ACP osteoporosis treatment guideline debated
DENVER – An endocrinologist and a primary care physician debate the merits of the American College of Physicians osteoporosis treatment guideline...
Conference Coverage
Romosozumab reduces fracture risk out to 36 months, with no signs of cardiovascular problems
Taking romosozumab followed by denosumab led to fewer fractures and greater bone density increases than did placebo followed by denosumab.
Conference Coverage
Teriparatide reduces fractures over risedronate in all subgroups with osteoporosis
DENVER – “I don’t think it’s a question of if, but when to use an anabolic therapy,” Dr. Fahrleitner-Pammer said.
Conference Coverage
Preferred osteoporosis treatment order with teriparatide, denosumab reaffirmed
DENVER – The findings reinforce the use of an anabolic agent followed by an antiresorptive agent, rather than the other way around.
From the Journals
PBC linked to increased risk of bone fracture
Multiple factors underlie the osteopenic bone disease in PBC.
Conference Coverage
Incidental hip CT scans could serve as osteoporosis screen
DENVER – Bone mineral density and femoral strength calculated from CT scans that had been taken for another purpose performed better than did DXA...
Conference Coverage
Reduced fracture risk maintained in abaloparatide extension study
At least one new vertebral fracture occurred in 0.9% of the women in the abaloparatide-alendronate group and in 5.6% of the placebo-alendronate...
Feature
Worsening osteoporosis care for RA patients shows need for action
Appropriate osteoporosis care in patients with rheumatoid arthritis is suboptimal and has been declining steadily over the past decade, but new...
Conference Coverage
Study finds low risk for jaw osteonecrosis with denosumab for postmenopausal osteoporosis
An analysis of a 7-year, open-label extension study of denosumab in women found a 0.05% overall rate of jaw osteonecrosis and a 0.7% rate...